Aflac Cancer Center and Blood Disorders Service of Children’s Healthcare of Atlanta
Caring for Children with Cancer and Blood Disorders
Recognized as one of the leading pediatric cancer, hematology and BMT programs in the country, the Aflac Cancer Center is committed to providing children and young adults with a brighter future through advanced medical treatment, family-centered care, a child-friendly environment and innovative research.
Our Programs
WhytheAflacCancerCenter?
-
- We are recognized as one of the top pediatric cancer centers by U.S.News & World Report
- We are one of the highest volume pediatric centers in the country which allows us to provide families with an entire team of professionals, dedicated hospital space, advanced technology and innovative research
- We treat an average of 350 new cancer cases each year—nearly one per day
- We care for more than 100 children with brain tumors each year
- We are highly skilled and experienced in treating children and young adults with all forms of cancer—from the most common to the rarest
- We are home to a robust Cancer Survivor Program—we follow nearly 1,000 survivors
- We are recognized as a national leader in transplanting children with sickle cell disease—we have cured more than 30 children
- We have the largest pediatric sickle cell program in the country, with more than 1,600 patients
- We are a national referral center for pediatric cancer and blood disorders—treating patients from 43 different states throughout the U.S.
CommittedtoPediatricResearch
-
In conjunction with Emory University School of Medicine, the Aflac Cancer Center is dedicated to finding the most effective treatments and cures for children with cancer and blood disorders. Search our clinical trial database for a list of our current trials.
- We are home to one of the largest pediatric clinical trials programs in the country—we offer our patients access to approixmately 250 clinical trials, including some of the most novel treatment options in the country
- Our physicians are widely regarded in national clinical trials and collaborative studies of the Children’s Oncology Group (COG), the National Cancer Institute, the National Institutes of Health and the Pediatric Blood and Marrow Transplant Consortium—among others.
- 100 percent of our hematologists/oncologists are researchers—as a result, every child is evaluated for clinical trial participation
- We are one of only 3 centers in the Southeast that is a member of the COG Phase I Consortium
- We were the recipient of a $1 million EUREKA grant—allowing researchers and engineers to investigate a novel bioengineering solution aimed at pediatric brain tumors